Endothelin-1 signaling in vascular physiology and pathophysiology

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 202-214

  Sandoval, Yessica Haydee Gomez ^a   Atef, Mohammed Emehdi ^a   Lévesque, Louis Olivier ^a   Li, Yuan ^a   Anand Srivastava, Madhu B ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atherosclerosis; Diabetes; ET 1; ET 1 signaling; ET 1 synthesis; ETA B receptors; Hypertension

Indexed keywords

ADENYLATE CYCLASE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; CALCIUM;

ARTICLE; ATHEROSCLEROSIS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DIABETES MELLITUS; HUMAN; HYPERTENSION; MITOGENESIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHOINOSITIDE METABOLISM; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; CYTOLOGY; METABOLISM; PHYSIOLOGY; SMOOTH MUSCLE FIBER;

ADENYLATE CYCLASE; ANIMALS; ATHEROSCLEROSIS; CALCIUM; DIABETES MELLITUS; ENDOTHELIN-1; HUMANS; HYPERTENSION; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION;

EID: 84922469163     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140226122054     Document Type: Article

References (156)

1. [1] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. [2] Hynynen MM, Khalil RA. The vascular endothelin system in hypertension--recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006;1:95-108.
3. [3] Lu MH, Chao CF, Tsai SH, et al. Autocrine effects of endothelin on in vitro proliferation of vascular smooth muscle cells from spontaneously hypertensive and normotensive rats. Clin Exp Hypertens 2006;28:463-74.
4. [4] Sugo S, Minamino N, Shoji H, et al. Regulation of endothelin-1 production in cultured rat vascular smooth muscle cells. J Cardiovasc Pharmacol 2001;37:25-40.
5. [5] Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76.
6. [6] Matsumoto H, Suzuki N, Onda H, et al. Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 1989;164:74-80.
7. [7] Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem 1989;264:14613-6.
8. [8] Takeji T, Nakaya Y, Kamada M, et al. Effect of a novel vasoconstrictor endothelin-1 (1-31) on human umbilical artery. Biochem Biophys Res Commun 2000;270:622-4.
9. [9] Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 1992;90:1023-31.
10. [10] Pinet F. What is the role of endothelin system?. Med Sci (Paris) 2004;20:339-45.
11. [11] Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-40.
12. [12] Blais V, Fugere M, Denault JB, et al. Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett 2002;524:43-8.
13. [13] D'Orleans-Juste P, Plante M, Honore JC, et al. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003;81:503-10.
14. [14] Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007;5:45-52.
15. [15] Maguire JJ, Johnson CM, Mockridge JW, et al. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol 1997;122:1647-54.
16. [16] Hanehira T, Kohno M, Yoshikawa J. Endothelin production in cultured vascular smooth muscle cells--modulation by the atrial, brain, and C-type natriuretic peptide system. Metabolism 1997;46:487-93.
17. [17] Lu MH, Chao CF, Huang CG, et al. Coculture of vascular endothelial cells and smooth muscle cells from spontaneously hypertensive rats. Clin Exp Hypertens 2003;25:413-25.
18. [18] Maemura K, Kurihara H, Morita T, et al. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 1992;38 Suppl 1:29-35.
19. [19] Malek AM, Zhang J, Jiang J, et al. Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J Mol Cell Cardiol 1999;31:387-99.
20. [20] Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-90.
21. [21] Kohno M, Yokokawa K, Horio T, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 1992;70:241-7.
22. [22] Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2.
23. [23] Takagi Y, Ninomiya H, Sakamoto A, et al. Structural basis of G protein specificity of human endothelin receptors. A study with endothelinA/B chimeras. J Biol Chem 1995;270:10072-8.
24. [24] Vogelsang M, Broede-Sitz A, Schafer E, et al. Endothelin ETA-receptors couple to inositol phosphate formation and inhibition of adenylate cyclase in human right atrium. J Cardiovasc Pharmacol 1994;23:344-7.
25. [25] Wu-Wong JR, Dixon DB, Opgenorth TJ. Effects of human plasma proteins on endothelin binding and function. J Cardiovasc Pharmacol 1998;31 (Suppl 1):S164-8.
26. [26] Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003;8:107-15.
27. [27] Brunner F, Bras-Silva C, Cerdeira AS, et al. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006;111:508-31.
28. [28] Eguchi S, Hirata Y, Imai T, et al. Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature. Endocrinology 1993;132:524-9.
29. [29] Ortega Mateo A, de Artinano AA. Highlights on endothelins: a review. Pharmacol Res 1997;36:339-51.
30. [30] Stjernquist M. Endothelins--vasoactive peptides and growth factors. Cell Tissue Res 1998;292:1-9.
31. [31] Amer MS. Cyclic nucleotides in disease; on the biochemical etiology of hypertension. Life Sci 1975;17:1021-38.
32. [32] Krauss G. Biochemistry of signal transduction and regulation.: (4 ed.). Weinheim; Chichester: Wiley-VCH.; 2008.
33. [33] Gilman AG. G proteins and dual control of adenylate cyclase. Cell 1984;36:577-9.
34. [34] Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995;80:249-57.
35. [35] Davis A, Hogarth K, Fernandes D, et al. Functional significance of protein kinase A activation by endothelin-1 and ATP: negative regulation of SRF-dependent gene expression by PKA. Cell Signal 2003;15:597-604.
36. [36] Yazawa H, Iida-Kubota E, Honma Y, et al. Characterization of the endothelin receptor in primary cultures of human aortic smooth muscle cells. Jpn J Pharmacol 1993;63:313-8.
37. [37] Fukami K. Structure, regulation, and function of phospholipase C isozymes. J Biochem 2002;131:293-9.
38. [38] Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001;70:281-312.
39. [39] Otto JC, Kelly P, Chiou ST, et al. Alterations in an inositol phosphate code through synergistic activation of a G protein and inositol phosphate kinases. Proc Natl Acad Sci USA 2007;104:15653-8.
40. [40] Bell RM, Hannun YA, Loomis CR. Mechanism of regulation of protein kinase C by lipid second messengers. Symp Fundam Cancer Res 1986;39:145-56.
41. [41] Chua BH, Krebs CJ, Chua CC, et al. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 1992;262:E412-6.
42. [42] Assender JW, Irenius E, Fredholm BB. Endothelin-1 causes a prolonged protein kinase C activation and acts as a co-mitogen in vascular smooth muscle cells. Acta Physiol Scand 1996;157:451-60.
43. [43] McNair LL, Salamanca DA, Khalil RA. Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension 2004;43:897-904.
44. [44] Lassegue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens 2004;17:852-60.
45. [45] Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 2004;19:488-93.
46. [46] Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993;21:294-300.
47. [47] Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003;107:1053-8.
48. [48] Callera GE, Touyz RM, Teixeira SA, et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003;42:811-7.
49. [49] Diederich D, Skopec J, Diederich A, et al. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994;23:957-61.
50. [50] Diederich D, Skopec J, Diederich A, et al. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994;266:H1153-61.
51. [51] Galle J, Lehmann-Bodem C, Hubner U, et al. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of O(2)(-) formation. Nephrol Dial Transplant 2000;15:339-46.
52. [52] Sedeek MH, Llinas MT, Drummond H, et al. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension 2003;42:806-10.
53. [53] Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010;299:H1959-67.
54. [54] Karin M, Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995;5:747-57.
55. [55] Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999;274:8347-50.
56. [56] Jankov RP, Kantores C, Belcastro R, et al. A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005;288:L1162-70.
57. [57] Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-60.
58. [58] Sumitomo M, Milowsky MI, Shen R, et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001;61:3294-8.
59. [59] Daou GB, Srivastava AK. Reactive oxygen species mediate Endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic Biol Med 2004;37:208-15.
60. [60] Gomez Sandoval YH, Levesque LO, Li Y, et al. Role of epidermal growth factor receptor transactivation in endothelin-1-induced enhanced expression of Gi protein and proliferation in A10 vascular smooth muscle cells. Can J Physiol Pharmacol 2013;91:221-7.
61. [61] Biscardi JS, Maa MC, Tice DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
62. [62] Keely SJ, Calandrella SO, Barrett KE. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular ca(2+), PYK-2, and p60(src). J Biol Chem 2000;275:12619-25.
63. [63] Luttrell LM, Hawes BE, van Biesen T, et al. Role of c-Src tyrosine kinase in G protein-coupled receptor-and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996;271:19443-50.
64. [64] Saito S, Frank GD, Mifune M, et al. Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. J Biol Chem 2002;277:44695-700.
65. [65] Devary Y, Gottlieb RA, Smeal T, et al. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 1992;71:1081-91.
66. [66] Robin P, Boulven I, Desmyter C, et al. ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. Am J Physiol Cell Physiol 2002;283:C251-60.
67. [67] Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
68. [68] Zhang YM, Wang KQ, Zhou GM, et al. Endothelin-1 promoted proliferation of vascular smooth muscle cell through pathway of extracellular signal-regulated kinase and cyclin D1. Acta Pharmacol Sin 2003;24:563-8.
69. [69] Kwon S, Lee WJ, Fang LH, et al. Mitogen-activated protein kinases partially regulate endothelin-1-induced contractions through a myosin light chain phosphorylation-independent pathway. J Vet Med Sci 2003;65:225-30.
70. [70] Hashim S, Li Y, Anand-Srivastava MB. Small cytoplasmic domain peptides of natriuretic peptide receptor-C attenuate cell proliferation through Gialpha protein/MAP kinase/PI3-kinase/AKT pathways. Am J Physiol Heart Circ Physiol 2006;291:H3144-53.
71. [71] Yue TL, Gu JL, Wang C, et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000;275:37895-901.
72. [72] Cheng CM, Hong HJ, Liu JC, et al. Crucial role of extracellular signal-regulated kinase pathway in reactive oxygen species-mediated endothelin-1 gene expression induced by endothelin-1 in rat cardiac fibroblasts. Mol Pharmacol 2003;63:1002-11.
73. [73] Sorokin A, Foschi M, Dunn MJ. Endothelin signalling and regulation of protein kinases in glomerular mesangial cells. Clin Sci (Lond) 2002;103 (Suppl 48):132S-6S.
74. [74] Yogi A, Callera GE, Montezano AC, et al. Endothelin-1, but not Ang II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007;27:1960-7.
75. [75] Iwasaki H, Eguchi S, Ueno H, et al. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 1999;140:4659-68.
76. [76] Abdel-Sayed S, Nussberger J, Aubert JF, et al. Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. Am J Hypertens 2003;16:515-21.
77. [77] Davenport AP, Ashby MJ, Easton P, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 1990;78:261-4.
78. [78] Donckier J, Stoleru L, Hayashida W, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995;92:106-13.
79. [79] Gulati A, Artwohl JE, Kumar A, et al. Endothelin-1-like immunoreactivity in a new rodent model of spontaneous hypertension. Am J Hypertens 1998;11:866-9.
80. [80] Kohno M, Murakawa K, Horio T, et al. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 1991;18:93-100.
81. [81] Kohno M, Yasunari K, Murakawa K, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990;88:614-8.
82. [82] Shichiri M, Hirata Y, Ando K, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990;15:493-6.
83. [83] Suzuki N, Miyauchi T, Tomobe Y, et al. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun 1990;167:941-7.
84. [84] Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-8.
85. [85] Kobayashi T, Miyauchi T, Iwasa S, et al. Corresponding distributions of increased endothelin-B receptor expression and increased endothelin-1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis. Pathol Int 2000;50:929-36.
86. [86] Lerman A, Webster MW, Chesebro JH, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 1993;88:2923-8.
87. [87] Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
88. [88] Winkles JA, Alberts GF, Brogi E, et al. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993;191:1081-8.
89. [89] Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008;199:237-47.
90. [90] Tada T, Nawata J, Wang H, et al. Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension. Cardiovasc Res 2008;80:346-53.
91. [91] Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
92. [92] Wang C, Liu J, Guo F, et al. Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2009;389:537-42.
93. [93] Browatzki M, Schmidt J, Kubler W, et al. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2000;95:98-105.
94. [94] Babaei S, Picard P, Ravandi A, et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000;48:158-67.
95. [95] Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998;95:14367-72.
96. [96] Wan S, Yim AP, Johnson JL, et al. The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Cardiovasc Surg 2004;127:1317-22.
97. [97] Dagassan PH, Breu V, Clozel M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996;27:147-53.
98. [98] Iwasa S, Fan J, Shimokama T, et al. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 1999;146:93-100.
99. [99] Pernow J, Bohm F, Johansson BL, et al. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol 2000;36:S418-20.
100. [100] Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
101. [101] Li L, Roumeliotis N, Sawamura T, et al. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 2004;95:877-83.
102. [102] Morawietz H, Duerrschmidt N, Niemann B, et al. Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun 2001;284:961-5.
103. [103] Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000;275:12633-8.
104. [104] Ergul A, Johansen JS, Stromhaug C, et al. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J Pharmacol Exp Ther 2005;313:70-7.
105. [105] Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005;1:100-10.
106. [106] Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007;101:455-64.
107. [107] Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000;49:1239-48.
108. [108] Sachidanandam K, Harris A, Hutchinson J, et al. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood) 2006;231:1016-21.
109. [109] Collier A, Leach JP, McLellan A, et al. Plasma endothelinlike immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 1992;15:1038-40.
110. [110] Hargrove GM, Dufresne J, Whiteside C, et al. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000;58:1534-45.
111. [111] Khan ZA, Chakrabarti S. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol 2003;81:622-34.
112. [112] Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
113. [113] Keynan S, Khamaisi M, Dahan R, et al. Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 2004;41:131-40.
114. [114] Chen S, Mukherjee S, Chakraborty C, et al. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol 2003;284:C263-72.
115. [115] Fukuda G, Khan ZA, Barbin YP, et al. Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab Res Rev 2005;21:367-75.
116. [116] Cheng ZJ, Vaskonen T, Tikkanen I, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001;37:433-9.
117. [117] Janssen U, Vassiliadou A, Riley SG, et al. The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J Nephrol 2004;17:769-73.
118. [118] Elgebaly MM, Kelly A, Harris AK, et al. Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1. Can J Physiol Pharmacol 2008;86:358-64.
119. [119] Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63.
120. [120] Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993;265:E783-93.
121. [121] Tappia PS, Asemu G, Aroutiounova N, et al. Defective sarcolemmal phospholipase C signaling in diabetic cardiomyopathy. Mol Cell Biochem 2004;261:193-9.
122. [122] Yang JM, Cho CH, Kong KA, et al. Increased expression of Galphaq protein in the heart of streptozotocin-induced diabetic rats. Exp Mol Med 1999;31:179-84.
123. [123] Descorbeth M, Anand-Srivastava MB. High glucose increases the expression of Gq/11alpha and PLC-beta proteins and associated signaling in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2008;295:H2135-42.
124. [124] Ramana KV, Friedrich B, Tammali R, et al. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 2005;54:818-29.
125. [125] Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-503.
126. [126] Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589-96.
127. [127] Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-23.
128. [128] Maritim AC, Sanders RA, Watkins JB, 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
129. [129] Benrezzak O, Marois H, Daull P, et al. Profile of endothelin isopeptides and markers of oxidative stress alongside the onset of streptozotocin-type I diabetes in rats. J Cardiovasc Pharmacol 2004;44 (Suppl 1):S168-72.
130. [130] Elgebaly MM, Portik-Dobos V, Sachidanandam K, et al. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vasc Pharmacol 2007;47:125-30.
131. [131] Matsumoto T, Ishida K, Nakayama N, et al. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 2009;296:H1388-97.
132. [132] Naruse M, Takagi S, Tanabe A, et al. Augmented expression of tissue endothelin-1 messenger RNA is a common feature in hypertensive rats. J Cardiovasc Pharmacol 2000;36:S195-7.
133. [133] Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61.
134. [134] Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994;24:183-8.
135. [135] McMahon EG, Palomo MA, Brown MA, et al. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993;6:667-73.
136. [136] Douglas SA, Gellai M, Ezekiel M, et al. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens 1994;12:561-7.
137. [137] Ohno A, Naruse M, Kato S, et al. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J Hypertens 1992;10:781-5.
138. [138] Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33:753-8.
139. [139] Lauth M, Berger MM, Cattaruzza M, et al. Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery. Hypertension 2000;35:648-54.
140. [140] Anand-Srivastava MB. Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition. Biochem J 1992;288 (Pt 1):79-85.
141. [141] Anand-Srivastava MB, de Champlain J, Thibault C. DOCA-salt hypertensive rat hearts exhibit altered expression of G-proteins. Am J Hypertens 1993;6:72-5.
142. [142] Cahill PA, Wu Y, Sitzmann JV. Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits. J Clin Invest 1994;93:2691-700.
143. [143] Ge C, Garcia R, Anand-Srivastava MB. Enhanced expression of Gialpha protein and adenylyl cyclase signaling in aortas from 1 kidney 1 clip hypertensive rats. Can J Physiol Pharmacol 2006;84:739-46.
144. [144] Thibault C, Anand-Srivastava MB. Altered expression of G-protein mRNA in spontaneously hypertensive rats. FEBS Lett 1992;313:160-4.
145. [145] Lappas G, Daou GB, Anand-Srivastava MB. Oxidative stress contributes to the enhanced expression of Gialpha proteins and adenylyl cyclase signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2005;23:2251-61.
146. [146] Michel JB, De Roux N, Plissonnier D, et al. Pathophysiological role of the vascular smooth muscle cell. J Cardiovasc Pharmacol 1990;16 Suppl 1:S4-11.
147. [147] Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005;90:449-55.
148. [148] de Nucci G, Gryglewski RJ, Warner TD, et al. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988;85:2334-8.
149. [149] Touyz RM, Deschepper C, Park JB, et al. Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens 2002;20:1127-34.
150. [150] Xu Q, Liu Y, Gorospe M, et al. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J Clin Invest 1996;97:508-14.
151. [151] Barman SA, Marrero MB. Mechanism of endothelin-1 activation of MAP kinases in neonatal pulmonary vascular smooth muscle. Lung 2005;183:425-39.
152. [152] Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.
153. [153] Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2001;281:L1058-67.
154. [154] Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
155. [155] Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6.
156. [156] Rafikova O, Rafikov R, Kumar S, et al. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med 2013;56:28-43.